Laboratory:Hachioji

Laboratory:Hachioji
TEST NAME |
SPECIMEN REQUIREMENT (mL) |
CONTAINER | CAP COLOR | STORE TEMPERATURE (STABILITY) |
TURNAROUND TIME (DAY) |
METHODOLOGY | REFERENCE RANGE (UNIT) |
BLOOD COLLECTION TIME |
---|---|---|---|---|---|---|---|---|
|
serum
0.5 |
S7P ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
Concentration of the elimination phase: 0.8-2.0 (ng/mL) |
6 hours postdose-Immediately before the next administration(elimination phase) |
Amiodarone
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
(ng/mL) | Immediately before the next administration(Trough concentration) |
Bepridil
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() (21 days) |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
250-800 (ng/mL) |
|
Aprindine
|
serum
0.3 |
S7P ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
0.25-1.25 (μg/mL) |
Oral:Immediately before the next administration(Trough concentration)Postdose2-4 hours (Peak concent |
Aprindine
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
0.25-1.25 (μg/mL) |
Oral:Immediately before the next administration(Trough concentration)Postdose2-4 hours (Peak concent |
Disopyramide
|
serum
0.3 |
S7P ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
2.0-5.0 (μg/mL) |
Immediately before the next administration(Trough concentration) |
Disopyramide
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
2.0-5.0 (μg/mL) |
Immediately before the next administration(Trough concentration) |
|
serum
0.3 |
S7P ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
1.2-5.0 (μg/mL) |
Intravenous:2 hours postdose Intravenous drip infusion:6-12 hours |
Mexilethine
|
serum
0.3 |
S7P ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
0.5-2.0 (μg/mL) |
Oral:Immediately before the next administration(Trough concentration) Intravenous:Whenever necess |
|
serum
0.4 |
S7P ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
4.0-10.0 (μg/mL) |
Immediately before the next administration(Trough concentration) |
|
plasma
0.4 |
PH5 ↓ A00 |
![]() |
![]() |
2-4 |
EIA Enzyme immunoassay (EIA) |
4.0-10.0 (μg/mL) |
Immediately before the next administration(Trough concentration) |
Propranolol
|
serum
0.3 |
S7P ↓ A00 |
![]() |
![]() |
4-10 |
HPLC High performance liquid chromatography (HPLC) |
50-100 (ng/mL) |
Immediately before the next administration(Trough concentration) |
Propranolol
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() |
4-10 |
HPLC High performance liquid chromatography (HPLC) |
50-100 (ng/mL) |
Immediately before the next administration(Trough concentration) |
Pilsicainide
|
serum
0.3 |
S7P ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
0.2-0.9 (μg/mL) |
Immediately before the next administration(Trough concentration) |
Pilsicainide
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
0.2-0.9 (μg/mL) |
Immediately before the next administration(Trough concentration) |
Propafenone
|
serum
0.3 |
S7P ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
(ng/mL) | |
Cibenzoline
|
serum
0.3 |
S7P ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
Trough concentration 70-250 (ng/mL) |
Immediately before morning administration(Trough concentration) |
Cibenzoline
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
Trough concentration 70-250 (ng/mL) |
Immediately before morning administration(Trough concentration) |
Pirmenol
|
plasma
1.3 |
PH5 ↓ A00 |
![]() |
![]() |
3-6 |
HPLC High performance liquid chromatography (HPLC) |
400.0以上 (ng/mL) |
Whenever necessary |
Quinidine
|
serum
0.4 |
S7P ↓ A00 |
![]() |
![]() |
2-8 |
EIA Enzyme immunoassay (EIA) |
2.0-6.0 (μg/mL) |
Immediately before the next administration(Trough concentration) |
Quinidine
|
plasma
0.4 |
PH5 ↓ A00 |
![]() |
![]() |
2-8 |
EIA Enzyme immunoassay (EIA) |
2.0-6.0 (μg/mL) |
Immediately before the next administration(Trough concentration) |
Flecainide
|
serum
0.3 |
S7P ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
200-1000 (ng/mL) |
Immediately before the next administration(Trough concentration) |
Flecainide
|
plasma
0.3 |
PH5 ↓ A00 |
![]() |
![]() |
3-5 |
LC/MS/MS Liquid chromatography-tandem mass spectrometry (LC/MS/MS) |
200-1000 (ng/mL) |
Immediately before the next administration(Trough concentration) |